|
Market Closed -
Nasdaq
07:00:00 27/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 65.11 USD | +0.90% |
|
+4.63% | +48.55% |
| 10/10 | Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says | MT |
| 09/10 | RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating | MT |
Company Valuation: Exelixis, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,784 | 5,174 | 7,460 | 9,510 | 11,799 | 15,989 | - | - |
| Change | - | -10.54% | 44.19% | 27.47% | 24.07% | 35.51% | - | - |
| Enterprise Value (EV) 1 | 4,317 | 3,865 | 6,465 | 8,399 | 10,740 | 15,245 | 14,367 | 13,242 |
| Change | - | -10.45% | 67.25% | 29.91% | 27.88% | 41.94% | -5.76% | -7.83% |
| P/E | 25.4x | 28.6x | 36.9x | 18.9x | 15.8x | 20x | 16.6x | 12.6x |
| PBR | 2.64x | 2.09x | 3.21x | 4.18x | 5.32x | 6.2x | 4.55x | 3.38x |
| PEG | - | -1.3x | 2.3x | 0x | 0.3x | 1.2x | 0.8x | 0.4x |
| Capitalization / Revenue | 4.03x | 3.21x | 4.08x | 4.39x | 5.09x | 6.26x | 5.51x | 4.82x |
| EV / Revenue | 3.01x | 2.4x | 3.53x | 3.87x | 4.63x | 5.97x | 4.95x | 3.99x |
| EV / EBITDA | 14.4x | 17.4x | 32.9x | 13.3x | 11.9x | 14x | 11.2x | 8.3x |
| EV / EBIT | 15.1x | 19.2x | 37.8x | 13.9x | 12.3x | 14.8x | 11.2x | 8.4x |
| EV / FCF | 12.8x | 17.2x | 22.1x | 12.5x | 12.3x | 18.7x | 17x | 9.5x |
| FCF Yield | 7.8% | 5.8% | 4.53% | 8% | 8.15% | 5.34% | 5.88% | 10.5% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.72 | 0.56 | 0.65 | 1.76 | 2.78 | 3.253 | 3.921 | 5.147 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 1,435 | 1,611 | 1,830 | 2,169 | 2,320 | 2,554 | 2,902 | 3,315 |
| EBITDA 1 | 300.3 | 222.4 | 196.6 | 633.4 | 901.2 | 1,091 | 1,279 | 1,595 |
| EBIT 1 | 286.7 | 201.5 | 170.9 | 604.6 | 872.2 | 1,031 | 1,286 | 1,576 |
| Net income 1 | 231.1 | 182.3 | 207.8 | 521.3 | 782.6 | 820.4 | 1,002 | 1,258 |
| Net Debt 1 | -1,467 | -1,308 | -995.3 | -1,111 | -1,059 | -744.5 | -1,623 | -2,747 |
| Reference price 2 | 18.28 | 16.04 | 23.99 | 33.30 | 43.83 | 65.11 | 65.11 | 65.11 |
| Nbr of stocks (in thousands) | 316,397 | 322,561 | 310,974 | 285,579 | 269,203 | 247,782 | - | - |
| Announcement Date | 17/2/22 | 7/2/23 | 6/2/24 | 11/2/25 | 10/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 19.84x | 5.97x | 13.97x | -.--% | 15.99B | |
| 18.83x | 6.63x | 13.18x | 1.58% | 64.69B | |
| 30.16x | 8x | 26.2x | 0.05% | 54.78B | |
| 36.79x | 6.53x | 19.51x | 0.88% | 53.49B | |
| 35.59x | 3.45x | 14.87x | -.--% | 45.98B | |
| 49.71x | 5.74x | 31.52x | -.--% | 42.94B | |
| -19.41x | 187.75x | -20.66x | -.--% | 40.08B | |
| 28.93x | 8.21x | 21.27x | 0.37% | 33.52B | |
| 27.67x | 5.83x | 15.12x | -.--% | 23.97B | |
| 32.59x | 5.97x | 20.28x | -.--% | 23.67B | |
| Average | 26.07x | 24.41x | 15.53x | 0.29% | 39.91B | |
| Weighted average by Cap. | 26.44x | 24.55x | 15.83x | 0.41% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- EXEL Stock
- Valuation Exelixis, Inc.
Select your edition
All financial news and data tailored to specific country editions
